221 related articles for article (PubMed ID: 31686907)
1. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A
Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
[TBL] [Abstract][Full Text] [Related]
3. Role of vandetanib in the management of medullary thyroid cancer.
Brassard M; Rondeau G
Biologics; 2012; 6():59-66. PubMed ID: 22500115
[TBL] [Abstract][Full Text] [Related]
4. Selective use of vandetanib in the treatment of thyroid cancer.
Fallahi P; Di Bari F; Ferrari SM; Spisni R; Materazzi G; Miccoli P; Benvenga S; Antonelli A
Drug Des Devel Ther; 2015; 9():3459-70. PubMed ID: 26170630
[TBL] [Abstract][Full Text] [Related]
5. Treating medullary thyroid cancer in the age of targeted therapy.
Cabanillas ME; Hu MI; Jimenez C; Grubbs EG; Cote GJ
Int J Endocr Oncol; 2014; 1(2):203-216. PubMed ID: 25908961
[TBL] [Abstract][Full Text] [Related]
6. Recent Updates on the Management of Medullary Thyroid Carcinoma.
Kim BH; Kim IJ
Endocrinol Metab (Seoul); 2016 Sep; 31(3):392-399. PubMed ID: 27586449
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in thyroid cancer: an extensive review of the literature.
Bikas A; Vachhani S; Jensen K; Vasko V; Burman KD
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1299-1313. PubMed ID: 27367142
[TBL] [Abstract][Full Text] [Related]
10. Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.
Martins RS; Jesus TT; Cardoso L; Soares P; Vinagre J
J Pers Med; 2023 Jul; 13(7):. PubMed ID: 37511745
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
12. Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer.
Pozo K; Zahler S; Ishimatsu K; Carter AM; Telange R; Tan C; Wang S; Pfragner R; Fujimoto J; Grubbs EG; Takahashi M; Oltmann SC; Bibb JA
Oncotarget; 2018 Dec; 9(102):37662-37675. PubMed ID: 30701022
[TBL] [Abstract][Full Text] [Related]
13. Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer.
Deshpande H; Roman S; Thumar J; Sosa JA
Clin Med Insights Oncol; 2011; 5():213-21. PubMed ID: 21836817
[TBL] [Abstract][Full Text] [Related]
14. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma.
Giunti S; Antonelli A; Amorosi A; Santarpia L
Int J Endocrinol; 2013; 2013():803171. PubMed ID: 23509459
[TBL] [Abstract][Full Text] [Related]
15. Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy.
Lodish M; Gkourogianni A; Bornstein E; Sinaii N; Fox E; Chuk M; Marcus L; Akshintala S; Balis F; Widemann B; Stratakis CA
Int J Pediatr Endocrinol; 2015; 2015(1):3. PubMed ID: 25972901
[TBL] [Abstract][Full Text] [Related]
16. New drugs for medullary thyroid cancer: new promises?
Spitzweg C; Morris JC; Bible KC
Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
[TBL] [Abstract][Full Text] [Related]
17. Medullary thyroid cancer--current treatment strategy, novel therapies and perspectives for the future.
Sugawara M; Ly T; Hershman JM
Horm Cancer; 2012 Dec; 3(5-6):218-26. PubMed ID: 23011723
[TBL] [Abstract][Full Text] [Related]
18. Vandetanib for the treatment of metastatic medullary thyroid cancer.
Degrauwe N; Sosa JA; Roman S; Deshpande HA
Clin Med Insights Oncol; 2012; 6():243-52. PubMed ID: 22723734
[TBL] [Abstract][Full Text] [Related]
19. Putative BRAF activating fusion in a medullary thyroid cancer.
Kasaian K; Wiseman SM; Walker BA; Schein JE; Hirst M; Moore RA; Mungall AJ; Marra MA; Jones SJ
Cold Spring Harb Mol Case Stud; 2016 Mar; 2(2):a000729. PubMed ID: 27148585
[TBL] [Abstract][Full Text] [Related]
20. Vandetanib-Induced Hyponatremia and Torsades De Pointes: A Case Report.
Ashraf S; Shah N; Saad M; Jyala A; Vittorio TJ
Cureus; 2022 Apr; 14(4):e24556. PubMed ID: 35651469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
